Startups
AdAlta (ASX:1AD) is the pioneer of a novel technology platform that mimics the shape and engineers key stability features of the antigen binding domain of shark antibodies into human proteins to create unique compounds, known as i-bodies, for therapeutic intervention in disease.
AdAlta is utilising the power of its i-body technology platform to develop a pipeline of i-bodies (drugs), with an initial focus on treating fibrotic diseases.
AdAlta is utilising the power of its i-body technology platform to develop a pipeline of i-bodies (drugs), with an initial focus on treating fibrotic diseases.
Overview
Location
Australia, Victoria, Melbourne
Employees
1-10
Total raised
$692.6K
Founded date
2007
Investors 1
| Date | Name | Website |
| Sign up to see | Sign up to see | Sign up to see |
Funding Rounds 1
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
Mentions in press and media 6
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Jan 20, 2022 | AdAlta : Presentation to Share Cafe Webinar | For personal use only 20 January 2022 ASX Announcement ADALTA UPDATED CORPORATE PRESENTATION AND INVESTOR WEBINAR MELBOURNE Australia, 20 January 2022: AdAlta Limited (ASX:1AD), the clinical stage biotechnology company developing novel ther... |
| Jan 4, 2022 | AdAlta : Presentation Conference Schedule - January 2022 | For personal use only 4 January 2022 ASX Announcement ADALTA PRESENTING AT JANUARY BIOTECH CONFERENCES MELBOURNE Australia, 4 January 2022: AdAlta Limited (ASX:1AD), the clinical stage drug discovery company developing novel therapeutic pro... |
| Dec 15, 2021 | AdAlta : Cash Position and Corporate Presentation | For personal use only 15 December 2021 ASX Announcement CASH POSITION, CARINA NEWS AND CORPORATE PRESENTATION Key points: Cash position of A$6.46 million at 30 November 2021 (excluding A$3.75 million Placement proceeds) Research plan agreed... |
| Nov 29, 2021 | AdAlta : AGM presentations & first iCAR-T data | For personal use only 29 November 2021 ASX Announcement AGM: CHAIR ADDRESS, CEO PRESENTATION AND FIRST i-CAR-T DATA MELBOURNE Australia, 29 November 2021: AdAlta Limited (ASX:1AD), the clinical stage drug discovery company developing novel ... |
| Aug 24, 2021 | ASX Announcement: AdAlta and Carina Biotech to develop next-generation CAR-T cancer therapeutics | Highlights: AdAlta and Carina Biotech enter a collaboration agreement to develop i-body enabled CAR-T cancer immunotherapies against up to five solid tumour antigen targets Combining Carina's advanced CAR-T platform technologies with AdAlta... |
Reviews 0
FAQ about AdAlta Limited
When was AdAlta Limited founded?
AdAlta Limited was founded in 2007.
How much funding has AdAlta Limited raised?
AdAlta Limited has raised $692.6K in total across 1 funding round.
What has the press written about AdAlta Limited?
Parsers VC has collected 6 articles mentioning AdAlta Limited, among them “AdAlta : Presentation to Share Cafe Webinar” (Jan 20, 2022) and “AdAlta : Presentation Conference Schedule - January 2022” (Jan 4, 2022).
Is AdAlta Limited still active?
Yes, AdAlta Limited is active; its latest activity on Parsers VC dates from Jan 24, 2022.